PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3280124-3 1988 We find that these retinoic acid-induced changes are accompanied by a marked decrease in the levels of p53 and p53 mRNA. Tretinoin 19-32 tumor protein p53 Homo sapiens 103-106 3280124-3 1988 We find that these retinoic acid-induced changes are accompanied by a marked decrease in the levels of p53 and p53 mRNA. Tretinoin 19-32 tumor protein p53 Homo sapiens 111-114 33423323-7 2021 Kyoto Encyclopedia of Genes and Genomes pathway results indicated that most DEGs caused by SCRV infection were identified in the immune system (retinoic acid-inducible gene-I-like receptor/Toll-like receptor/nucleotide-binding oligomerization domain-like receptor/C-type lectin receptor signalling pathway), cellular processes, cell growth and death (p53 signalling pathway, cellular senescence, apoptosis and phagosome), and metabolism. Tretinoin 144-157 tumor protein p53 Homo sapiens 351-354 2981174-0 1985 Lack of correlation between loss of anchorage-independent growth and levels of transformation-specific p53 protein in retinoic acid-treated F9 embryonal carcinoma cells. Tretinoin 118-131 tumor protein p53 Homo sapiens 103-106 32741018-0 2020 Novel evidence for retinoic acid-induced G (Rig-G) as a tumor suppressor by activating p53 signaling pathway in lung cancer. Tretinoin 19-32 tumor protein p53 Homo sapiens 87-90 34047175-0 2021 A Pin1/PML/P53 axis activated by retinoic acid in NPM-1c-acute myeloid leukemia. Tretinoin 33-46 tumor protein p53 Homo sapiens 11-14 34047175-2 2021 We reported that ex vivo, RA triggers NPM-1c degradation, P53 activation and growth arrest. Tretinoin 26-28 tumor protein p53 Homo sapiens 58-61 32124141-7 2020 CONCLUSION: The overall results of the study strongly suggest that all-trans retinoic acid enhances the effect of Fra-1 on inhibiting cervical cancer proliferation and metabolism in vitro, and also influences the expression of MDM2/P53/P21 and LDHA. Tretinoin 77-90 tumor protein p53 Homo sapiens 232-235 31427086-7 2019 All-trans-retinoic acid (ATRA) treatment of MYCN/NCYM-amplified neuroblastoma CHP134 cells induced TAp63 and reduced p53 expressions, accompanied by downregulation of MYCN/NCYM expressions. Tretinoin 0-23 tumor protein p53 Homo sapiens 117-120 32124141-2 2020 The results show that all-trans retinoic acid enhances the effect of Fra-1 on inhibiting cervical cancer proliferation and the glucose consumption, its effect on the loss of mitochondrial membrane potential, on the decreasing of lactic acid as well as ATP, and also influences the expression of MDM2/P53/P21 and LDHA. Tretinoin 32-45 tumor protein p53 Homo sapiens 300-303 31427086-7 2019 All-trans-retinoic acid (ATRA) treatment of MYCN/NCYM-amplified neuroblastoma CHP134 cells induced TAp63 and reduced p53 expressions, accompanied by downregulation of MYCN/NCYM expressions. Tretinoin 25-29 tumor protein p53 Homo sapiens 117-120 29156743-1 2017 All-trans retinoic acid (ATRA), the most biologically active metabolite of vitamin A, is known to induce p14 expression via promoter hypomethylation to activate the p14-MDM2-p53 pathway, which leads to activation of the p53-dependent apoptotic pathway and subsequent induction of apoptosis in human hepatoma cells. Tretinoin 0-23 tumor protein p53 Homo sapiens 174-177 28927457-2 2017 All-trans retinoic acid (ATRA) and isotretinoin (13-cis retinoic acid) enhance p53 expression. Tretinoin 0-23 tumor protein p53 Homo sapiens 79-82 28927457-2 2017 All-trans retinoic acid (ATRA) and isotretinoin (13-cis retinoic acid) enhance p53 expression. Tretinoin 25-29 tumor protein p53 Homo sapiens 79-82 30415163-0 2018 A novel all-trans retinoic acid derivative inhibits proliferation and induces apoptosis of myelodysplastic syndromes cell line SKM-1 cells via up-regulating p53. Tretinoin 18-31 tumor protein p53 Homo sapiens 157-160 29440484-0 2018 Synergistic and additive effect of retinoic acid in circumventing resistance to p53 restoration. Tretinoin 35-48 tumor protein p53 Homo sapiens 80-83 29068287-1 2017 All-trans retinoic acid (ATRA), the most biologically active metabolite of vitamin A, is known to activate p14 expression via promoter hypermethylation to induce p53-dependent apoptosis in human hepatocytes. Tretinoin 0-23 tumor protein p53 Homo sapiens 162-165 29068287-1 2017 All-trans retinoic acid (ATRA), the most biologically active metabolite of vitamin A, is known to activate p14 expression via promoter hypermethylation to induce p53-dependent apoptosis in human hepatocytes. Tretinoin 25-29 tumor protein p53 Homo sapiens 162-165 29068287-2 2017 In this study, we found that the oncogenic hepatitis B virus (HBV) X protein (HBx) of HBV, derived from both overexpression and 1.2-mer replicon systems, suppresses ATRA-induced apoptosis in p53-positive human hepatocytes. Tretinoin 165-169 tumor protein p53 Homo sapiens 191-194 29068287-4 2017 As a result, HBx was able to impair the potential of ATRA to activate apoptosis-related molecules, including Bax, p53-upregulated modulator of apoptosis, caspase-9, caspase-3 and poly (ADP-ribose) polymerase. Tretinoin 53-57 tumor protein p53 Homo sapiens 114-117 29068287-5 2017 In conclusion, the present study provides a new oncogenic action mechanism of HBx, namely by suppressing the anticancer potential of ATRA to induce p53-dependent apoptosis in HBV-infected hepatocytes. Tretinoin 133-137 tumor protein p53 Homo sapiens 148-151 29156743-1 2017 All-trans retinoic acid (ATRA), the most biologically active metabolite of vitamin A, is known to induce p14 expression via promoter hypomethylation to activate the p14-MDM2-p53 pathway, which leads to activation of the p53-dependent apoptotic pathway and subsequent induction of apoptosis in human hepatoma cells. Tretinoin 0-23 tumor protein p53 Homo sapiens 220-223 29156743-1 2017 All-trans retinoic acid (ATRA), the most biologically active metabolite of vitamin A, is known to induce p14 expression via promoter hypomethylation to activate the p14-MDM2-p53 pathway, which leads to activation of the p53-dependent apoptotic pathway and subsequent induction of apoptosis in human hepatoma cells. Tretinoin 25-29 tumor protein p53 Homo sapiens 174-177 29156743-1 2017 All-trans retinoic acid (ATRA), the most biologically active metabolite of vitamin A, is known to induce p14 expression via promoter hypomethylation to activate the p14-MDM2-p53 pathway, which leads to activation of the p53-dependent apoptotic pathway and subsequent induction of apoptosis in human hepatoma cells. Tretinoin 25-29 tumor protein p53 Homo sapiens 220-223 29156743-2 2017 In the present study, we found that hepatitis C virus (HCV) Core derived from ectopic expression or HCV infection overcomes ATRA-induced apoptosis in p53-positive hepatoma cells. Tretinoin 124-128 tumor protein p53 Homo sapiens 150-153 29156743-6 2017 Based on these observations, we conclude that HCV Core executes its oncogenic potential by suppressing the p53-dependent apoptosis induced by ATRA in human hepatoma cells. Tretinoin 142-146 tumor protein p53 Homo sapiens 107-110 25827071-4 2015 The potential of ATRA to stabilize p53 was almost completely abolished by knock-down of p14 in HepG2 cells and was not observed in p14-negative A549 cells. Tretinoin 17-21 tumor protein p53 Homo sapiens 35-38 25465239-0 2016 Gene Expression Profile of NF-kappaB, Nrf2, Glycolytic, and p53 Pathways During the SH-SY5Y Neuronal Differentiation Mediated by Retinoic Acid. Tretinoin 129-142 tumor protein p53 Homo sapiens 60-63 27177208-0 2016 A novel all-trans retinoic acid derivative 4-amino-2-trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP. Tretinoin 18-31 tumor protein p53 Homo sapiens 228-231 27177208-14 2016 Moreover, the fluorescent density of p53 was higher in the nuclei after exposure to ATPR than that in the ATRA group. Tretinoin 106-110 tumor protein p53 Homo sapiens 37-40 25827071-0 2015 All-trans retinoic acid induces p53-depenent apoptosis in human hepatocytes by activating p14 expression via promoter hypomethylation. Tretinoin 10-23 tumor protein p53 Homo sapiens 32-35 25827071-2 2015 Here we found that ATRA induces apoptosis in p53-positive HepG2 cells, but not in p53-negative Hep3B cells. Tretinoin 19-23 tumor protein p53 Homo sapiens 45-48 25827071-7 2015 Ectopic expression of DNA methyltransferase 1 almost completely abolished the potential of ATRA to activate the p14-MDM2-p53 pathway and induce p53-dependent apoptosis. Tretinoin 91-95 tumor protein p53 Homo sapiens 121-124 25827071-7 2015 Ectopic expression of DNA methyltransferase 1 almost completely abolished the potential of ATRA to activate the p14-MDM2-p53 pathway and induce p53-dependent apoptosis. Tretinoin 91-95 tumor protein p53 Homo sapiens 144-147 24399651-0 2014 The impact of arsenic trioxide and all-trans retinoic acid on p53 R273H-codon mutant glioblastoma. Tretinoin 45-58 tumor protein p53 Homo sapiens 62-65 24399651-6 2014 The results showed that U87-p53(R273H) cells generated more rapid neurosphere growth than U87-p53(wt) but inhibition of neurosphere proliferation was seen with both ATO and ATRA. Tretinoin 173-177 tumor protein p53 Homo sapiens 28-31 24399651-7 2014 U87-p53(R273H) neurospheres showed resistance to differentiation into glial cells and neuronal cells with ATO and ATRA exposure. Tretinoin 114-118 tumor protein p53 Homo sapiens 4-7 24399651-8 2014 ATO was able to generate apoptosis at high doses and proliferation of U87-p53(wt) and U87-p53(R273H) cells was reduced with ATO and ATRA in a dose-dependent manner. Tretinoin 132-136 tumor protein p53 Homo sapiens 74-77 24399651-8 2014 ATO was able to generate apoptosis at high doses and proliferation of U87-p53(wt) and U87-p53(R273H) cells was reduced with ATO and ATRA in a dose-dependent manner. Tretinoin 132-136 tumor protein p53 Homo sapiens 90-93 24399651-9 2014 Elevated pERK1/2 and p53 expression was seen in U87-p53(R273H) neurospheres, which could be reduced with ATO and ATRA treatment. Tretinoin 113-117 tumor protein p53 Homo sapiens 21-24 24399651-9 2014 Elevated pERK1/2 and p53 expression was seen in U87-p53(R273H) neurospheres, which could be reduced with ATO and ATRA treatment. Tretinoin 113-117 tumor protein p53 Homo sapiens 52-55 21633925-3 2012 In the present study, we show that retinoic acid enhances the cytostatic and apoptogenic properties of the novel adamantyl retinoid ST1926 in a panel of neuroblastoma cells with different p53 status and caspase 8 expression, resulting in synergistic effects as assessed by Combination Index and Isobologram analysis. Tretinoin 35-48 tumor protein p53 Homo sapiens 188-191 24078252-2 2014 We performed genome-wide profiling of p53 chromatin interactions and target gene expression in human embryonic stem cells (hESCs) in response to early differentiation, induced by retinoic acid, versus DNA damage, caused by adriamycin. Tretinoin 179-192 tumor protein p53 Homo sapiens 38-41 25140197-5 2014 Therefore, combination of ATRA with DAC and SAHA represents promising tool for therapy of leukemic disease with nonfunctional p53 signalization. Tretinoin 26-30 tumor protein p53 Homo sapiens 126-129 23851445-8 2013 Furthermore, the ability of ATRA to induce senescence is reduced in p14(ARF)-depleted melanocytes, and we provide proof-of-concept that ATRA can induce irreversible growth arrest in melanoma cells with an intact RARbeta-p14(ARF) signaling axis, independent of p16(INK4A) and p53 status. Tretinoin 136-140 tumor protein p53 Homo sapiens 275-278 23588680-0 2013 All-trans retinoic acid upregulates the expression of p53 via Axin and inhibits the proliferation of glioma cells. Tretinoin 10-23 tumor protein p53 Homo sapiens 54-57 23588680-2 2013 In the present study, we demonstrated that ATRA activated the expression of p53 via Axin and induced cell cycle arrest at the G1/S phase and apoptosis of glioma cells. Tretinoin 43-47 tumor protein p53 Homo sapiens 76-79 23588680-6 2013 Furthermore, loss-of-function of Axin in glioma cells by RNAi blocked ATRA-induced cell cycle phase arrest and apoptosis via downregulation of p53. Tretinoin 70-74 tumor protein p53 Homo sapiens 143-146 25140197-0 2014 Decitabine and SAHA-induced apoptosis is accompanied by survivin downregulation and potentiated by ATRA in p53-deficient cells. Tretinoin 99-103 tumor protein p53 Homo sapiens 107-110 23022267-0 2013 Tyrosine phosphatase inhibitors combined with retinoic acid can enhance differentiation of neuroblastoma cells and trigger ERK- and AKT-dependent, p53-independent senescence. Tretinoin 46-59 tumor protein p53 Homo sapiens 147-150 21633925-8 2012 Although not modulated, p53 appeared to enhance cells responsiveness to retinoid/ATRA combination. Tretinoin 81-85 tumor protein p53 Homo sapiens 24-27 20067883-15 2009 beta-carotene, lycopene and all-trans retinoic acid alone and in combination with docetaxel were found to influence the expression of bcl-2 and p53 antigen in the cells examined. Tretinoin 38-51 tumor protein p53 Homo sapiens 144-147 20686816-1 2012 Unlike its cytotoxicity in p53-functional cell lines, Nutlin-1, the small-molecule inhibitor of murine double minute (MDM2), significantly enhanced the differentiation-inducing activity of all-trans retinoic acid (ATRA) in HL60 and NB4 cells (p53-nonfunctional) but not in U937 cells (p53 wild-type). Tretinoin 214-218 tumor protein p53 Homo sapiens 243-246 20686816-1 2012 Unlike its cytotoxicity in p53-functional cell lines, Nutlin-1, the small-molecule inhibitor of murine double minute (MDM2), significantly enhanced the differentiation-inducing activity of all-trans retinoic acid (ATRA) in HL60 and NB4 cells (p53-nonfunctional) but not in U937 cells (p53 wild-type). Tretinoin 214-218 tumor protein p53 Homo sapiens 243-246 20686816-2 2012 Moreover, we demonstrated that the synergistic differentiation-inducing activity of Nutlin-1 combined with ATRA appeared in a p53-independent manner. Tretinoin 107-111 tumor protein p53 Homo sapiens 126-129 22389628-4 2012 In response to retinoic acid, CBP/p300 acetylates p53 at lysine 373, which leads to dissociation from E3-ubiquitin ligases HDM2 and TRIM24. Tretinoin 15-28 tumor protein p53 Homo sapiens 50-53 22389628-7 2012 Induction of p53 levels is a key step: RNA-interference-mediated knockdown of p53 delays differentiation, whereas depletion of negative regulators of p53 or ectopic expression of p53 yields spontaneous differentiation of hESCs, independently of retinoic acid. Tretinoin 245-258 tumor protein p53 Homo sapiens 13-16 21843507-2 2011 Here, we show that ATRA induces promoter hypomethylation of p16 and p21 via down-regulation of DNA methyltransferases 1, 3a, and 3b to facilitate binding of Ets1/2 to the p16 promoter and p53 to the p21 promoter, resulting in up-regulation of their expression and subsequent induction of cellular senescence in HepG2 cells. Tretinoin 19-23 tumor protein p53 Homo sapiens 188-191 20598227-0 2010 Role of acetylated p53 in regulating the expression of map2 in retinoic acid-induced P19 cells. Tretinoin 63-76 tumor protein p53 Homo sapiens 19-22 20598227-1 2010 OBJECTIVE: To investigate the regulatory mechanisms of acetylated p53 in the expression of microtubule-associated protein-2 (MAP2) in neuronal differentiation of P19 cells induced by all-trans retinoic acid (RA). Tretinoin 208-210 tumor protein p53 Homo sapiens 66-69 19723072-5 2009 Chromatin immunoprecipitation analysis has revealed phenyl butyrate and its combinations with RA and vitamin B3 cause histone H4 acetylation in the p21 promoter regions corresponding to p53 and/or Sp1 sites. Tretinoin 94-96 tumor protein p53 Homo sapiens 186-189 19216755-11 2009 Also, Chmp1A silencing diminished the increase of Chmp1A, P53 and phospho-P53 protein expression induced by ATRA. Tretinoin 108-112 tumor protein p53 Homo sapiens 58-61 19216755-11 2009 Also, Chmp1A silencing diminished the increase of Chmp1A, P53 and phospho-P53 protein expression induced by ATRA. Tretinoin 108-112 tumor protein p53 Homo sapiens 74-77 21061155-4 2011 Laser confocal microscopy results reveal that PHB colocalized with the expression products of c-myc, c-fos, p53, and Rb, but the colocalization region was altered after RA treatment. Tretinoin 169-171 tumor protein p53 Homo sapiens 108-111 18511453-7 2008 Silencing of KLF4 expression by KLF4-specific small interfering RNA (siRNA) abrogated the inducing effects of ATRA on p53, SM22alpha and alpha-SMA expression and neutralized the inhibitory effects of ATRA on SMemb expression and VSMC proliferation and migration. Tretinoin 110-114 tumor protein p53 Homo sapiens 118-121 17293044-4 2007 Treatment of the cells with all trans retinoic acid (RA) generates a neuron-like, morphological change of differentiation, and results in the activation of ERK and Akt pathways, an inhibition of the nuclear translocation of p53 induced by GA, and induces higher resistance to the GA-induced apoptosis. Tretinoin 38-51 tumor protein p53 Homo sapiens 224-227 17449938-7 2007 In addition, minoxidil plus ATRA elevated phosphorylated Erk, phosphorylated Akt and the ratio of Bcl-2/Bax, but decreased the expressions of P53 and P21 more effectively than by minoxidil alone. Tretinoin 28-32 tumor protein p53 Homo sapiens 142-145 17449938-8 2007 Our results suggest that minoxidil plus ATRA would additively enhance hair growth by mediating dual functions: 1) the prolongation of cell survival by activating the Erk and Akt signaling pathways, and 2) the prevention of apoptosis of DPCs and epithelial cells by increasing the ratio of Bcl-2/Bax and downregulating the expressions of P53 and P21. Tretinoin 40-44 tumor protein p53 Homo sapiens 337-340 16568081-5 2006 ATRA-mediated apoptosis in CHP134 and NB-39-nu cells was associated with a significant activation of caspase-9 and caspase-3 as well as cytoplasmic release of cytochrome c from mitochondria in a p53-independent manner. Tretinoin 0-4 tumor protein p53 Homo sapiens 195-198 16752155-3 2007 RA treatment resulted in an increase of p21, p27 and p53 protein levels and G1 arrest in UM cells, which correlated with significant down-modulation of surface Her2/neu proto-oncogene expression. Tretinoin 0-2 tumor protein p53 Homo sapiens 53-56 17234770-5 2007 Expression array analyses revealed that RA induces the expression of several genes involved in cell cycle regulation, including the p53-controlled antiproliferative gene B-cell translocation gene, member 2 (Btg2) and the BTG family member Tob1. Tretinoin 40-42 tumor protein p53 Homo sapiens 132-135 16935849-6 2007 ATRA induced apoptosis and increased the expression of p53 protein in a dose-dependent fashion. Tretinoin 0-4 tumor protein p53 Homo sapiens 55-58 15674351-2 2005 We have previously shown that p53 repression in TGCT-derived human embryonal carcinoma (EC) is relieved upon treatment with all-trans retinoic acid (RA), resulting in enhanced p53 transactivation activity. Tretinoin 134-147 tumor protein p53 Homo sapiens 30-33 16087156-0 2005 Knockdown of p53 by RNAi in ES cells facilitates RA-induced differentiation into muscle cells. Tretinoin 49-51 tumor protein p53 Homo sapiens 13-16 16087156-5 2005 With RA treatment, silencing of p53 by RNAi in ES cells leads to dominant muscle cell production but lack of neuronal cell, indicating that p53 indeed plays a role during muscle and neuronal fate commitment. Tretinoin 5-7 tumor protein p53 Homo sapiens 32-35 16087156-5 2005 With RA treatment, silencing of p53 by RNAi in ES cells leads to dominant muscle cell production but lack of neuronal cell, indicating that p53 indeed plays a role during muscle and neuronal fate commitment. Tretinoin 5-7 tumor protein p53 Homo sapiens 140-143 15790450-4 2005 The objective of this study was to determine if p53 is involved in the mechanism of RA radiosensitization. Tretinoin 84-86 tumor protein p53 Homo sapiens 48-51 15790450-6 2005 RESULTS: RA (5 microM 9-cis-RA) radiosensitized the SiHa and CC-1 cell lines that contain HPV-degraded p53, but did not radiosensitize the SW962 cell line, which is HPV negative and contains wild-type p53, nor the C33a cell line, which contains mutant p53 (R273C). Tretinoin 9-11 tumor protein p53 Homo sapiens 103-106 15790450-6 2005 RESULTS: RA (5 microM 9-cis-RA) radiosensitized the SiHa and CC-1 cell lines that contain HPV-degraded p53, but did not radiosensitize the SW962 cell line, which is HPV negative and contains wild-type p53, nor the C33a cell line, which contains mutant p53 (R273C). Tretinoin 9-11 tumor protein p53 Homo sapiens 201-204 15790450-6 2005 RESULTS: RA (5 microM 9-cis-RA) radiosensitized the SiHa and CC-1 cell lines that contain HPV-degraded p53, but did not radiosensitize the SW962 cell line, which is HPV negative and contains wild-type p53, nor the C33a cell line, which contains mutant p53 (R273C). Tretinoin 9-11 tumor protein p53 Homo sapiens 201-204 15674351-2 2005 We have previously shown that p53 repression in TGCT-derived human embryonal carcinoma (EC) is relieved upon treatment with all-trans retinoic acid (RA), resulting in enhanced p53 transactivation activity. Tretinoin 134-147 tumor protein p53 Homo sapiens 176-179 15674351-2 2005 We have previously shown that p53 repression in TGCT-derived human embryonal carcinoma (EC) is relieved upon treatment with all-trans retinoic acid (RA), resulting in enhanced p53 transactivation activity. Tretinoin 149-151 tumor protein p53 Homo sapiens 30-33 15674351-2 2005 We have previously shown that p53 repression in TGCT-derived human embryonal carcinoma (EC) is relieved upon treatment with all-trans retinoic acid (RA), resulting in enhanced p53 transactivation activity. Tretinoin 149-151 tumor protein p53 Homo sapiens 176-179 15674351-11 2005 While RA alone had no effect on p53-NRD activity, cotreatment with RA and the histone deacetylase inhibitor trichostatin-A (TSA) completely relieved p53-NRD-mediated repression. Tretinoin 67-69 tumor protein p53 Homo sapiens 149-152 15374966-0 2004 Retinoic acid increases the expression of p53 and proapoptotic caspases and sensitizes keratinocytes to apoptosis: a possible explanation for tumor preventive action of retinoids. Tretinoin 0-13 tumor protein p53 Homo sapiens 42-45 15374966-8 2004 Inhibition of p53 and caspases with alpha-pifithrin and z-Val-Ala-Asp-fluoromethyl ketone, respectively, blocked UVB- and doxorubicin-induced apoptosis in ATRA-treated KCs. Tretinoin 155-159 tumor protein p53 Homo sapiens 14-17 15374966-6 2004 Analysis by real-time PCR and Western blot revealed that ATRA treatment strongly increased the mRNA and protein expression of p53 and caspase-3, -6, -7, and -9, which are key regulators of apoptosis. Tretinoin 57-61 tumor protein p53 Homo sapiens 126-129 15374966-9 2004 Analogous to the observed ATRA effects in monolayer cultures, in vitro-generated organotypic skin cultures reacted with up-regulation of p53 and proapoptotic caspases and displayed increased sensitivity to UVB-induced apoptosis. Tretinoin 26-30 tumor protein p53 Homo sapiens 137-140 15374966-7 2004 UVB irradiation of ATRA-treated cells but not of control cells led to the accumulation of p53 protein and of its target gene Noxa. Tretinoin 19-23 tumor protein p53 Homo sapiens 90-93 15254726-5 2004 Expression of p53, p21 and bax was increased, and bcl-2 was decreased in melanoma cells after exposure to atRA at different concentrations for various periods of time. Tretinoin 106-110 tumor protein p53 Homo sapiens 14-17 15254726-0 2004 Expression profiles of p53, p21, bax and bcl-2 proteins in all-trans-retinoic acid treated primary and metastatic melanoma cells. Tretinoin 69-82 tumor protein p53 Homo sapiens 23-26 15254726-3 2004 In this study, we used a similar cell culture model system of matched primary and metastatic melanoma cells from the same patient to investigate whether p53 and bcl-2 family proteins were involved in atRA-induced apoptosis. Tretinoin 200-204 tumor protein p53 Homo sapiens 153-156 15254726-8 2004 These data indicate that p53, p21, bax and bcl-2 proteins were involved in atRA-induced apoptosis in melanoma cells. Tretinoin 75-79 tumor protein p53 Homo sapiens 25-28 11753676-4 2001 However, RA sensitive CA-OV3 cells expressed higher levels of p53, p27, p21, and p16 compared to RA resistant SK-OV3 cells. Tretinoin 9-11 tumor protein p53 Homo sapiens 62-65 14693485-0 2003 Effect of topical tretinoin, chemical peeling and dermabrasion on p53 expression in facial skin. Tretinoin 18-27 tumor protein p53 Homo sapiens 66-69 14693485-6 2003 Topical tretinoin therapy was found to induce a significant decrease in the expression of p53 up to 6 months of therapy followed by a significant increase after 10 months of therapy. Tretinoin 8-17 tumor protein p53 Homo sapiens 90-93 12139723-0 2002 Superior effect of 9-cis retinoic acid (RA) compared with all-trans RA and 13-cis RA on the inhibition of clonogenic cell growth and the induction of apoptosis in OCI/AML-2 subclones: is the p53 pathway involved? Tretinoin 40-42 tumor protein p53 Homo sapiens 191-194 12139723-1 2002 In the present study, the effects of 9-cis retinoic acid (RA) and 13-cis RA on acute myeloblastic leukaemia (AML) cell growth and the induction of apoptosis as well as its relationship with bcl-2 and p53 were compared with those of all-trans RA (ATRA). Tretinoin 58-60 tumor protein p53 Homo sapiens 200-203 12139723-4 2002 In addition, Western blotting revealed the most obvious translocation of p53 from cytosol to nucleus in the case of 9-cis RA, which was the only retinoid able to change the conformation of p53 from mutational to wild type, as demonstrated by flow cytometry. Tretinoin 122-124 tumor protein p53 Homo sapiens 73-76 12139723-4 2002 In addition, Western blotting revealed the most obvious translocation of p53 from cytosol to nucleus in the case of 9-cis RA, which was the only retinoid able to change the conformation of p53 from mutational to wild type, as demonstrated by flow cytometry. Tretinoin 122-124 tumor protein p53 Homo sapiens 189-192 11568584-0 2001 All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma. Tretinoin 0-23 tumor protein p53 Homo sapiens 77-80 11780391-6 2001 ATRA might induce p21WAF1/CIP1 expression in ATRA-sensitive cell lines through p53-dependent and p53-independent pathways. Tretinoin 0-4 tumor protein p53 Homo sapiens 79-82 11780391-6 2001 ATRA might induce p21WAF1/CIP1 expression in ATRA-sensitive cell lines through p53-dependent and p53-independent pathways. Tretinoin 0-4 tumor protein p53 Homo sapiens 97-100 10518116-10 1999 The opposite alteration of Bcl-2 (anti-apoptotic) and p53 (apoptotic) contents in SH-SY5Y cells with retinoic acid and staurosporine are attributed to the changes in cell vulnerability. Tretinoin 101-114 tumor protein p53 Homo sapiens 54-57 11464863-0 2001 Retinoic acid-induced apoptosis of the CHP134 neuroblastoma cell line is associated with nuclear accumulation of p53 and is rescued by the GDNF/Ret signal. Tretinoin 0-13 tumor protein p53 Homo sapiens 113-116 11464863-11 2001 The present results suggest that the RA-induced apoptosis of NBL cells is associated with activation of both the caspase cascade and the p53-mediated pathway with its nuclear translocation. Tretinoin 37-39 tumor protein p53 Homo sapiens 137-140 11100817-7 2000 Upon treatment with retinoic acid (RA) and dibutyryl cyclic AMP (dbcAMP), overall GSP staining were increased concomitant with suppression of nuclear m-p53. Tretinoin 20-33 tumor protein p53 Homo sapiens 152-155 11100817-7 2000 Upon treatment with retinoic acid (RA) and dibutyryl cyclic AMP (dbcAMP), overall GSP staining were increased concomitant with suppression of nuclear m-p53. Tretinoin 35-37 tumor protein p53 Homo sapiens 152-155 10929428-14 2000 Mutant p53 expression was more decreased in the EJ cells treated with RA or Ni(RA)2.3H2O than in the control. Tretinoin 70-72 tumor protein p53 Homo sapiens 7-10 10815802-3 2000 ATRA treatment of cells that express wild-type p53 (A549 and H460), or null p53 (H1299), or mutant p53 (H596) increased the number of TNF receptors, as determined by the specific binding of 125I-labeled TNF to these cells, in a dose- and time-dependent manner. Tretinoin 0-4 tumor protein p53 Homo sapiens 47-50 10815802-3 2000 ATRA treatment of cells that express wild-type p53 (A549 and H460), or null p53 (H1299), or mutant p53 (H596) increased the number of TNF receptors, as determined by the specific binding of 125I-labeled TNF to these cells, in a dose- and time-dependent manner. Tretinoin 0-4 tumor protein p53 Homo sapiens 76-79 10815802-3 2000 ATRA treatment of cells that express wild-type p53 (A549 and H460), or null p53 (H1299), or mutant p53 (H596) increased the number of TNF receptors, as determined by the specific binding of 125I-labeled TNF to these cells, in a dose- and time-dependent manner. Tretinoin 0-4 tumor protein p53 Homo sapiens 76-79 11465510-3 2001 In order to determine if the genotype of the p53 donor or the genotype of the sp donor determined the binding efficiency, p53 expression was induced by retinoic acid and sp synthesis by bleomycin. Tretinoin 152-165 tumor protein p53 Homo sapiens 122-125 10940651-0 2000 p53 pathway in apoptosis induced by all-trans-retinoic acid in acute myeloblastic leukaemia cells. Tretinoin 36-59 tumor protein p53 Homo sapiens 0-3 10940651-1 2000 The role of the p53 pathway in apoptosis induced by all-trans-retinoic acid (ATRA) was studied in 5 human acute myeloid leukaemia (AML) cell lines, OU-AML-3, -4, -5, -7 and -8, previously established and characterized by the authors. Tretinoin 52-75 tumor protein p53 Homo sapiens 16-19 10940651-1 2000 The role of the p53 pathway in apoptosis induced by all-trans-retinoic acid (ATRA) was studied in 5 human acute myeloid leukaemia (AML) cell lines, OU-AML-3, -4, -5, -7 and -8, previously established and characterized by the authors. Tretinoin 77-81 tumor protein p53 Homo sapiens 16-19 10518116-8 1999 The expression of the proteins of the protooncogene Bcl-2 and the tumor suppressor gene p53 following staurosporine or retinoic acid treatment was assessed by Western blot and immunocytochemistry. Tretinoin 119-132 tumor protein p53 Homo sapiens 88-91 10518116-9 1999 Retinoic acid increased Bcl-2 and decreased p53 levels, whereas staurosporine decreased Bcl-2 and increased p53 levels. Tretinoin 0-13 tumor protein p53 Homo sapiens 44-47 9436034-6 1997 ATRA also arrested the cell cycle in G1 and reduced the percentage of the S phase cell in terms of wild type p53, leading to apoptosis in part. Tretinoin 0-4 tumor protein p53 Homo sapiens 109-112 10364268-0 1999 Retinoic acid confers resistance to p53-dependent apoptosis in SH-SY5Y neuroblastoma cells by modulating nuclear import of p53. Tretinoin 0-13 tumor protein p53 Homo sapiens 36-39 10364268-0 1999 Retinoic acid confers resistance to p53-dependent apoptosis in SH-SY5Y neuroblastoma cells by modulating nuclear import of p53. Tretinoin 0-13 tumor protein p53 Homo sapiens 123-126 10364268-3 1999 We examine here the possible contribution of the p53 pathway to the chemoresistance response associated with the RA treatment in NB cells. Tretinoin 113-115 tumor protein p53 Homo sapiens 49-52 10364268-4 1999 Upon treatment with RA (1-10 microM) for 4 days, the human NB cells, SH-SY5Y, developed resistance selectively to p53-dependent apoptotic stimuli including gamma-irradiation, etoposide, and 1-(5-isoquinolinyl sulfonyl)-2-methylpiperazine (H-7). Tretinoin 20-22 tumor protein p53 Homo sapiens 114-117 10364268-5 1999 Interestingly, RA affected the ability of H-7 to induce nuclear accumulation of the p53 protein without altering its effect on elevating the steady-state level of p53, suggesting that drug-induced up-regulation and nuclear accumulation of the wild-type p53 protein are separable processes. Tretinoin 15-17 tumor protein p53 Homo sapiens 84-87 10364268-6 1999 The modulation of nuclear import of p53 protein by RA may thus represent a potential mechanism by which certain tumor cells with the wild-type p53 gene develop resistance to chemotherapeutic agents. Tretinoin 51-53 tumor protein p53 Homo sapiens 36-39 10364268-6 1999 The modulation of nuclear import of p53 protein by RA may thus represent a potential mechanism by which certain tumor cells with the wild-type p53 gene develop resistance to chemotherapeutic agents. Tretinoin 51-53 tumor protein p53 Homo sapiens 143-146 10094816-3 1999 This RA-induced apoptosis was accompanied by p53-independent up-regulation of endogenous p21(CIPI/Waf1) and Bax proteins, as well as activation of p34(cdc2) kinase, and increase of Rb2 protein level and phosphorylation pattern. Tretinoin 5-7 tumor protein p53 Homo sapiens 45-48 9766444-7 1998 In contrast, the differentiation response of p53-negative U-937 cells to 1,25-dihydroxychole-calciferol or all-trans retinoic acid was enhanced by cAMP-inducing agents at optimal concentrations and inhibited at higher concentrations. Tretinoin 107-130 tumor protein p53 Homo sapiens 45-48 9718082-8 1998 An increase in the level of immunophenotypic expression of wild type p53 was also noted after treatment with all trans retinoic acid and 9-cis retinoic acid. Tretinoin 119-132 tumor protein p53 Homo sapiens 69-72 12548778-4 1999 In RA-sensitive cell lines, ATRA-induced G0/G1 arrest is associated with down regulaton of c-myc and hyperphosphorylated Rb expression, and up regulation of p21WAF1/CIP1 and p53 expression. Tretinoin 28-32 tumor protein p53 Homo sapiens 174-177 9950218-6 1999 Increased expression of p53 protein is observed in ATRA-treated HMECs at 72 h; however, initiation of G1-S-phase arrest starts at 24 h, suggesting that this observed induction of p53 is a secondary event. Tretinoin 51-55 tumor protein p53 Homo sapiens 24-27 9950218-6 1999 Increased expression of p53 protein is observed in ATRA-treated HMECs at 72 h; however, initiation of G1-S-phase arrest starts at 24 h, suggesting that this observed induction of p53 is a secondary event. Tretinoin 51-55 tumor protein p53 Homo sapiens 179-182 9950218-13 1999 Our results emphasize the chemotherapeutic potential of ATRA and antiestrogens, particularly for suppressing the growth of tumors lacking functional p53. Tretinoin 56-60 tumor protein p53 Homo sapiens 149-152 8476634-12 1993 These results demonstrate that RA regulates growth of HTGE cells mainly by upregulating the p53 gene; Ca2+, which enhances TGF-beta 1 expression, had no effect on growth. Tretinoin 31-33 tumor protein p53 Homo sapiens 92-95 9225073-0 1997 Modulation of p53, WAF1/p21 and BCL-2 expression during retinoic acid-induced differentiation of NB4 promyelocytic cells. Tretinoin 56-69 tumor protein p53 Homo sapiens 14-17 10743138-2 1997 The results indicated that after treated with ST and RA, the cells became well-differentiated, the cell growth was suppressed, contact suppress was partially recovered, colony forming was decreased, protooncogenes (C-myc bcl-2) protein was decreased, tumor suppressor gene (p53) protein was increased. Tretinoin 53-55 tumor protein p53 Homo sapiens 274-277 8082749-0 1994 Transient stabilization of p53 in non-small cell lung carcinoma cultures arrested for growth by retinoic acid. Tretinoin 96-109 tumor protein p53 Homo sapiens 27-30 8082749-3 1994 Levels of p53 transcripts remained unchanged during the time of increases in protein expression in retinoic acid-treated H460a cells, suggesting that a post-translational mechanism was involved in the increased expression of the protein. Tretinoin 99-112 tumor protein p53 Homo sapiens 10-13 8082749-4 1994 Pulse-chase analysis demonstrated that wild-type p53 was significantly more stabile in H460a cells treated with retinoic acid, exhibiting a half-life greater than 6 h, in contrast to 3 h for the protein in untreated control cells. Tretinoin 112-125 tumor protein p53 Homo sapiens 49-52 8082749-5 1994 The retinoic acid-mediated effect was specific for wild-type p53, since expression of mutant p53 in the H596b and H322j cell lines remained relatively unchanged even after 72 h exposure to retinoic acid. Tretinoin 4-17 tumor protein p53 Homo sapiens 61-64 8082749-5 1994 The retinoic acid-mediated effect was specific for wild-type p53, since expression of mutant p53 in the H596b and H322j cell lines remained relatively unchanged even after 72 h exposure to retinoic acid. Tretinoin 4-17 tumor protein p53 Homo sapiens 93-96 8082749-5 1994 The retinoic acid-mediated effect was specific for wild-type p53, since expression of mutant p53 in the H596b and H322j cell lines remained relatively unchanged even after 72 h exposure to retinoic acid. Tretinoin 189-202 tumor protein p53 Homo sapiens 61-64 8082749-5 1994 The retinoic acid-mediated effect was specific for wild-type p53, since expression of mutant p53 in the H596b and H322j cell lines remained relatively unchanged even after 72 h exposure to retinoic acid. Tretinoin 189-202 tumor protein p53 Homo sapiens 93-96 8082749-6 1994 We conclude that retinoic acid induces stabilization of wild-type p53 in NSCLC cells by a post-translational mechanism. Tretinoin 17-30 tumor protein p53 Homo sapiens 66-69 8082749-7 1994 Furthermore, increases in expression of p53 were not responsible for the retinoic acid-induced transient inhibition of growth of NSCLC cells, since the growth of H358 p53-null cells also was inhibited by retinoic acid. Tretinoin 204-217 tumor protein p53 Homo sapiens 167-170 8673928-3 1996 Differentiation of these teratocarcinoma cells with retinoic acid results in a marked decrease in p53 protein levels but is accompanied by a marked increase in p53-mediated transcriptional activity. Tretinoin 52-65 tumor protein p53 Homo sapiens 98-101 8673928-3 1996 Differentiation of these teratocarcinoma cells with retinoic acid results in a marked decrease in p53 protein levels but is accompanied by a marked increase in p53-mediated transcriptional activity. Tretinoin 52-65 tumor protein p53 Homo sapiens 160-163 7730147-6 1995 All-trans retinoic acid (all-trans RA) at 1 nM or granulocyte macrophage colony-stimulating factor (GM-CSF) at 35 pM inhibited the wt-p53-induced apoptosis over a 42-h treatment. Tretinoin 10-23 tumor protein p53 Homo sapiens 134-137 8476634-0 1993 Retinoic acid and calcium regulation of p53, transforming growth factor-beta 1, and transforming growth factor-alpha gene expression and growth in adenovirus 12-SV40-transformed human tracheal gland epithelial cells. Tretinoin 0-13 tumor protein p53 Homo sapiens 40-43 8476634-10 1993 RA inhibited both cell proliferation and AIG growth, which was accompanied by enhanced expression of p53. Tretinoin 0-2 tumor protein p53 Homo sapiens 101-104 34579932-0 2021 Expression of concern: "Tyrosine phosphatase inhibitors combined with retinoic acid can enhance differentiation of neuroblastoma cells and trigger ERK- and AKT-dependent, p53-independent senescence" Cancer Letters, Volume 328, Issue 1, 1 January 2013, Pages 44-54. Tretinoin 70-83 tumor protein p53 Homo sapiens 171-174 1741160-6 1992 Upon retinoic acid-induced differentiation of the LA-N-5 neuroblastoma cell line, the level of p53 protein declined, as did the level of p53 mRNA, but the half-life of the protein remained unchanged. Tretinoin 5-18 tumor protein p53 Homo sapiens 95-98 1741160-6 1992 Upon retinoic acid-induced differentiation of the LA-N-5 neuroblastoma cell line, the level of p53 protein declined, as did the level of p53 mRNA, but the half-life of the protein remained unchanged. Tretinoin 5-18 tumor protein p53 Homo sapiens 137-140 34832966-9 2021 Treatment of SK-N-FI and SK-N-Be(2) cells with doxorubicin, etoposide, cisplatin, and melphalan increased apoptosis and blocked the cycle in G2/M, while retinoic acid isomers induced apoptosis and decreased the percentage of cells in S phase in TP53 mutated SK-N-FI cells, but not in TP53 wild-type SK-N-Be(2) cells. Tretinoin 153-166 tumor protein p53 Homo sapiens 245-249 34832966-10 2021 Treatment with cisplatin, melphalan, or 9-cis RA decreased p53 expression levels in SK-N-FI cells but not in SK-N-Be (2). Tretinoin 46-48 tumor protein p53 Homo sapiens 59-62 34660779-4 2021 Treatment with PAC and ATRA induced cell cycle arrest at the G2/M phase and apoptosis by upregulating p53 and caspase-8 expression and increased the intracellular calcium (Ca2+) level possibly by enhancing Ca2+ uptake via plasma membrane channels. Tretinoin 23-27 tumor protein p53 Homo sapiens 102-105 35066375-2 2022 For this effect, ATRA downregulated both protein and enzyme activity levels of DNA methyltransferase 1 and 3b and activated E6AP expression via promoter hypomethylation in HepG2 cells but not in Hep3B cells, in which p53 was absent. Tretinoin 17-21 tumor protein p53 Homo sapiens 217-220 35066375-3 2022 Ectopic p53 expression but not E6AP overexpression restored the ability of ATRA to downregulate HCV Core levels in Hep3B cells, suggesting a direct role of p53 in the E6AP-mediated ubiquitination of HCV Core. Tretinoin 75-79 tumor protein p53 Homo sapiens 8-11 35066375-3 2022 Ectopic p53 expression but not E6AP overexpression restored the ability of ATRA to downregulate HCV Core levels in Hep3B cells, suggesting a direct role of p53 in the E6AP-mediated ubiquitination of HCV Core. Tretinoin 75-79 tumor protein p53 Homo sapiens 156-159